Profusa, Inc. Annual Report: A Simple Guide

I’ve put together this guide to help you understand how Profusa performed this year. My goal is to explain their complex filings in plain English so you can decide if this company fits your investment goals.

1. What does Profusa do?

Profusa is a digital health company that spent over a decade building a unique "biosensor" platform. Instead of bulky wearables, they use a tiny, soft hydrogel sensor injected under the skin. It tracks body chemistry—like oxygen or glucose—in real time. Because it is made of material similar to contact lenses, it avoids the scar tissue that causes other sensors to fail after a few weeks.

2025 was a major transition year. The company went public on July 11, 2025, raising $150 million. They are currently in a "pre-revenue" stage, meaning they focus on clinical trials and FDA approvals rather than selling products. They are also scaling up manufacturing to prepare for future demand.

2. Financial performance

Profusa reported $0 in product sales for the year ending December 31, 2025. They have relied on over $100 million in funding from venture investors and government grants, including $30 million from DARPA and the NIH.

The company reported a $42 million loss this year. This includes $28 million spent on research and development and $14 million in administrative costs from going public. They spend about $3.5 million per month, giving them enough cash to last roughly 18 months.

3. Major wins and challenges

• The Big Win: Their technology is built to last. While typical glucose monitors last two weeks, Profusa’s "Lumee Glucose" sensor has worked for up to nine months in trials. Because the sensor is passive and the reader is a reusable patch, they hope to offer a much cheaper alternative to current monitors.
• The Challenge: They have no products approved for sale in the U.S. Their success depends entirely on getting FDA approval. They must also prove that patients are comfortable with an "injectable" sensor rather than a simple adhesive patch.

4. Future outlook

Profusa has a busy roadmap for 2026 and 2027:

• Lumee Oxygen: They plan to launch this in late 2026 to help manage chronic wounds and artery disease.
• Lumee Glucose: They plan to submit this for regulatory review in early 2026. They hope to reach the 38 million Americans with Type 2 or pre-diabetes.
• The Strategy: Profusa wants to provide data for the telemedicine industry. By feeding real-time data into medical records, they aim to earn recurring income through licensing agreements.

5. Key risks

• Regulatory Hurdles: The FDA process is unpredictable. If they fail to get approval for their oxygen sensor by late 2026, they may run out of cash and need to issue more shares, which would reduce your ownership percentage.
• Competition: They face giants like Dexcom and Abbott, who control over 90% of the market and have massive distribution networks.
• Cash Flow: With no sales and high costs, the company needs more money. They will likely need to raise $75–$100 million before they become profitable, which they don't expect until at least 2028.

Final Thought for Investors: Profusa is a classic "high-risk, high-reward" play. You are essentially betting on their ability to clear the FDA hurdle and disrupt a market currently dominated by established giants. If you are comfortable with a company that won't be profitable for several years and may need to raise more capital, their long-lasting sensor technology offers a unique value proposition. If you prefer companies with steady cash flow and proven sales, this may be one to watch from the sidelines until they secure their first regulatory approval.